201 related articles for article (PubMed ID: 33235351)
41. Haploidentical transplantation outcomes for secondary acute myeloid leukemia: Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) study.
Li Z; Labopin M; Ciceri F; Blaise D; Tischer J; Ehninger G; Van Lint MT; Koc Y; Santarone S; Forcade E; Castagna L; Polge E; Mailhol A; Ruggeri A; Mohty M; Savani BN; Nagler A
Am J Hematol; 2018 Jun; 93(6):769-777. PubMed ID: 29536560
[TBL] [Abstract][Full Text] [Related]
42. Unrelated cord blood transplantation vs. HLA-matched sibling transplantation for adults with B-cell acute lymphoblastic leukemia in complete remission: superior OS for patients with long-term survival.
Sun G; Tang B; Song K; Wu Y; Tu M; Wan X; Yao W; Geng L; Qiang P; Zhu X
Stem Cell Res Ther; 2022 Oct; 13(1):500. PubMed ID: 36210439
[TBL] [Abstract][Full Text] [Related]
43. Allogeneic stem cell transplantation following relapse post autologous stem cell transplantation in adult patients with acute myeloid leukemia: A retrospective analysis of 537 patients from the Acute Leukemia Working Party of the EBMT.
Christopeit M; Labopin M; Gorin NC; Saraceni F; Passweg J; Forcade E; Maertens J; Van Lint MT; Bosi A; Niederwieser D; Ehninger G; Polge E; Mohty M; Nagler A
Am J Hematol; 2018 Dec; 93(12):1532-1542. PubMed ID: 30218444
[TBL] [Abstract][Full Text] [Related]
44. Allogeneic stem cell transplant in patients with acute myeloid leukemia and karnofsky performance status score less than or equal to 80%: A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation (EBMT).
Saraceni F; Labopin M; Forcade E; Kröger N; Socié G; Niittyvuopio R; Cornelissen JJ; Labussière-Wallet H; Blaise D; Choi G; Byrne JL; Guillerm G; Marchand T; Esteve J; Bazarbachi A; Savani B; Olivieri A; Nagler A; Mohty M
Cancer Med; 2021 Jan; 10(1):23-33. PubMed ID: 33242374
[TBL] [Abstract][Full Text] [Related]
45. A risk score system for stratifying the risk of relapse in B cell acute lymphocytic leukemia patients after allogenic stem cell transplantation.
Cao LQ; Zhou Y; Liu YR; Xu LP; Zhang XH; Wang Y; Chen H; Chen YH; Wang FR; Han W; Sun YQ; Yan CH; Tang FF; Mo XD; Liu KY; Fan QZ; Chang YJ; Huang XJ
Chin Med J (Engl); 2021 Mar; 134(10):1199-1208. PubMed ID: 33734137
[TBL] [Abstract][Full Text] [Related]
46. Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT.
Gilleece MH; Labopin M; Savani BN; Yakoub-Agha I; Socié G; Gedde-Dahl T; Blaise D; Byrne JL; Craddock C; Cornelissen JJ; Arcese W; Forcade E; Crawley C; Polge E; Mohty M; Nagler A
Leukemia; 2020 Jan; 34(1):87-99. PubMed ID: 31363160
[TBL] [Abstract][Full Text] [Related]
47. Measurable residual disease, FLT3-ITD mutation, and disease status have independent prognostic influence on outcome of allogeneic stem cell transplantation in NPM1-mutated acute myeloid leukemia.
Al Hamed R; Labopin M; Daguindau E; Niittyvuopio R; Huynh A; Socié G; Srour M; Henri Bourhis J; Kröger N; Tholouli E; Choi G; Poiré X; Martin H; Rubio MT; Jindra P; Blaise D; Beelen D; Labussière-Wallet H; Nagler A; Bazarbachi A; Mohty M
Cancer Med; 2022 Feb; 11(4):1068-1080. PubMed ID: 35048553
[TBL] [Abstract][Full Text] [Related]
48. Ikaros family zinc-finger 1 mutation is an independent factor for the poor prognosis of adult B-cell acute lymphoblastic leukemia, and allogeneic hematopoietic stem cell transplantation can improve clinical outcomes.
Tang S; Shen H; Qu C; Dai H; Zhu X; Xue S; Ding Z; Lu J; Wu D; Tang X
Bone Marrow Transplant; 2019 Feb; 54(2):236-243. PubMed ID: 29942002
[TBL] [Abstract][Full Text] [Related]
49. Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results.
Kebriaei P; Bassett R; Lyons G; Valdez B; Ledesma C; Rondon G; Oran B; Ciurea S; Alousi A; Popat U; Patel K; Ahmed S; Olson A; Bashir Q; Shah N; Jones R; Marin D; Rezvani K; Nieto Y; Khouri I; Qazilbash M; Hosing C; Shpall E; Champlin RE; Andersson BS
Biol Blood Marrow Transplant; 2017 Feb; 23(2):285-292. PubMed ID: 27816651
[TBL] [Abstract][Full Text] [Related]
50. Prognostic factors on graft-versus-host disease-free and relapse-free survival after allogeneic hematopoietic stem cell transplantation for adults with acute leukemia.
Tan J; Wang Y; Yu SJ; Ma YY; Lei HY; Liu QF
Leuk Res; 2017 Aug; 59():1-7. PubMed ID: 28527401
[TBL] [Abstract][Full Text] [Related]
51. Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT.
Rubio MT; Savani BN; Labopin M; Piemontese S; Polge E; Ciceri F; Bacigalupo A; Arcese W; Koc Y; Beelen D; Gülbas Z; Wu D; Santarone S; Tischer J; Afanasyev B; Schmid C; Giebel S; Mohty M; Nagler A
J Hematol Oncol; 2016 Mar; 9():25. PubMed ID: 26980295
[TBL] [Abstract][Full Text] [Related]
52. Favorable outcome of haploidentical hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia: a multicenter study in Southwest China.
Gao L; Zhang C; Gao L; Liu Y; Su Y; Wang S; Li B; Yang T; Yuan Z; Zhang X
J Hematol Oncol; 2015 Jul; 8():90. PubMed ID: 26208715
[TBL] [Abstract][Full Text] [Related]
53. Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
Sahebi F; Eikema DJ; Koster L; Kroger N; Meijer E; van Doesum JA; Rovira M; Koc Y; Angelucci E; Blaise D; Sammassimo S; McDonald A; Arroyo CH; Sanchez JF; Forcade E; Castagna L; Stölzel F; Sanz J; Tischer J; Ciceri F; Valcarcel D; Proia A; Hayden PJ; Beksac M; Yakoub-Agha I; Schönland S
Transplant Cell Ther; 2021 Dec; 27(12):999.e1-999.e10. PubMed ID: 34543768
[TBL] [Abstract][Full Text] [Related]
54. Comparison of Myeloablative versus Reduced-Intensity Conditioning Regimens in Allogeneic Stem Cell Transplantation Recipients with Acute Myelogenous Leukemia with Measurable Residual Disease-Negative Disease at the Time of Transplantation: A Retrospective Cohort Study.
Yu J; Du Y; Ahmad S; Patel RD; Varela JC; Chang CC; Mori S
Transplant Cell Ther; 2021 Aug; 27(8):663.e1-663.e6. PubMed ID: 33951497
[TBL] [Abstract][Full Text] [Related]
55. Haploidentical allogeneic hematopoietic stem cell transplantation compared to matched unrelated transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.
Gu B; Wu X; Chen G; Ma X; Jin Z; Tang X; Han Y; Fu C; Qiu H; Sun A; Wu D
Leuk Res; 2017 Aug; 59():41-46. PubMed ID: 28549237
[TBL] [Abstract][Full Text] [Related]
56. Sequential chemotherapy followed by reduced-intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of EBMT.
Ringdén O; Labopin M; Schmid C; Sadeghi B; Polge E; Tischer J; Ganser A; Michallet M; Kanz L; Schwerdtfeger R; Nagler A; Mohty M;
Br J Haematol; 2017 Feb; 176(3):431-439. PubMed ID: 27879990
[TBL] [Abstract][Full Text] [Related]
57. Postremission Consolidation by Autologous Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia in First Complete Remission (CR) and Negative Implications for Subsequent Allogeneic HCT in Second CR: A Study by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
Passweg JR; Labopin M; Christopeit M; Cornelissen J; Pabst T; Socié G; Russel N; Yakoub-Agha I; Blaise D; Gedde-Dahl T; Labussière-Wallet H; Malladi R; Forcade E; Maury S; Polge E; Lanza F; Gorin NC; Mohty M; Nagler A
Biol Blood Marrow Transplant; 2020 Apr; 26(4):659-664. PubMed ID: 31759159
[TBL] [Abstract][Full Text] [Related]
58. Impact of donor type on long-term graft-versus-host disease-free/relapse-free survival for adult acute lymphoblastic leukemia in first remission.
Yoon JH; Min GJ; Park SS; Park S; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Lee JW; Lee S
Bone Marrow Transplant; 2021 Apr; 56(4):828-840. PubMed ID: 33128028
[TBL] [Abstract][Full Text] [Related]
59. Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome.
Tomblyn MB; Arora M; Baker KS; Blazar BR; Brunstein CG; Burns LJ; DeFor TE; Dusenbery KE; Kaufman DS; Kersey JH; MacMillan ML; McGlave PB; Miller JS; Orchard PJ; Slungaard A; Tomblyn MR; Vercellotti GM; Verneris MR; Wagner JE; Weisdorf DJ
J Clin Oncol; 2009 Aug; 27(22):3634-41. PubMed ID: 19581540
[TBL] [Abstract][Full Text] [Related]
60. The impact of anti-thymocyte globulin on the outcomes of Patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation.
Nagler A; Dholaria B; Labopin M; Socie G; Huynh A; Itälä-Remes M; Deconinck E; Yakoub-Agha I; Cahn JY; Bourhis JH; Labussière-Wallet H; Chantepie S; Esteve J; Savani B; Mohty M
Leukemia; 2020 Apr; 34(4):1144-1153. PubMed ID: 31728052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]